持续肾脏替代治疗对硫酸黏菌素血药浓度、临床疗效和安全性的影响
该研究基于前瞻性多中心观察研究的注册数据,回顾性分析90例ICU重症感染患者,按是否接受血液净化分为CRRT组22例与非CRRT组68例。CRRT组APACHE II评分21.77±8.26 vs 18.01±6.34(P<0.05)、SOFA评分8.5(7.8,11.0)vs 6.0(4.0,9.0)(P<0.01)、血肌酐162.0(119.5,210.5)μmol/L vs 72.0(52.0,117.0)μmol/L(P<0.01)均更高。两组稳态谷浓度0.58±0.30 mg/L vs 0.64±0.25 mg/L(P=0.328)、稳态峰浓度1.02±0.37 mg/L vs 1.18±0.45 mg/L(P=0.133)及临床反应率68.2%(15/22)vs 80.9%(55/68)(P=0.213)均无显著差异。非CRRT组2例(2.9%)发生急性肾损伤。作者认为CRRT对硫酸黏菌素消除影响小,接受CRRT者需常规血药浓度监测。
要点
- CRRT组与非CRRT组稳态谷浓度0.58±0.30 mg/L vs 0.64±0.25 mg/L(P=0.328)、稳态峰浓度1.02±0.37 mg/L vs 1.18±0.45 mg/L(P=0.133),均无显著差异。
- CRRT组临床反应率68.2%(15/22) vs 非CRRT组80.9%(55/68),P=0.213,无显著差异。
- CRRT组APACHE II 21.77±8.26 vs 18.01±6.34(P<0.05)、SOFA 8.5(7.8,11.0) vs 6.0(4.0,9.0)(P<0.01)、血肌酐162.0(119.5,210.5)μmol/L vs 72.0(52.0,117.0)μmol/L(P<0.01)均更高。
- 非CRRT组急性肾损伤发生2例(2.9%),两组均未发现明显神经系统症状和皮肤色素沉着。
- 作者认为CRRT对硫酸黏菌素消除影响小,接受CRRT的患者需常规血药浓度监测(TDM)。
适用人群与场景
- ICU重症感染患者,来自本课题组既往关于硫酸黏菌素疗效与药代动力学特征的前瞻性多中心观察研究的临床注册数据。
- 按是否接受血液净化治疗分为CRRT组(22例)与非CRRT组(68例)。
- 两组性别、年龄、基础疾病、肝功能、感染病原体及部位、硫酸黏菌素剂量无显著差异。
研究设计与关键结果
- 研究类型:基于前瞻性多中心观察研究注册数据的回顾性分析;样本量90例(CRRT组22例,非CRRT组68例)。
- CRRT组APACHE II评分21.77±8.26 vs 非CRRT组18.01±6.34,P<0.05;CRRT组SOFA评分8.5(7.8,11.0) vs 非CRRT组6.0(4.0,9.0),P<0.01;CRRT组血肌酐162.0(119.5,210.5)μmol/L vs 非CRRT组72.0(52.0,117.0)μmol/L,P<0.01。
- 稳态谷浓度:CRRT组0.58±0.30 mg/L vs 非CRRT组0.64±0.25 mg/L,P=0.328,无显著差异。
- 稳态峰浓度:CRRT组1.02±0.37 mg/L vs 非CRRT组1.18±0.45 mg/L,P=0.133,无显著差异。
- 临床反应率:CRRT组68.2%(15/22) vs 非CRRT组80.9%(55/68),P=0.213,无显著差异。
- 安全性:非CRRT组发生急性肾损伤2例(2.9%);两组均未发现明显神经系统症状和皮肤色素沉着。
证据类型、等级与局限
- 证据类型:基于前瞻性多中心观察研究注册数据的回顾性分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为CRRT对硫酸黏菌素消除影响小。
- 作者认为接受硫酸黏菌素治疗的CRRT患者需常规进行血药浓度监测(TDM)。
- 本回顾性分析中CRRT组病情更重(APACHE II、SOFA、血肌酐更高),解读两组浓度与疗效比较时需考虑此基线差异。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To investigate the effects of continuous renal replacement therapy (CRRT) on plasma concentration, clinical efficacy and safety of colistin sulfate.
METHODS: Clinical data of patients received with colistin sulfate were retrospectively analyzed from our group's previous clinical registration study, which was a prospective, multicenter observation study on the efficacy and pharmacokinetic characteristics of colistin sulfate in patients with severe infection in intensive care unit (ICU). According to whether patients received blood purification treatment, they were divided into CRRT group and non-CRRT group. Baseline data (gender, age, whether complicated with diabetes, chronic nervous system disease, etc), general data (infection of pathogens and sites, steady-state trough concentration, steady-state peak concentration, clinical efficacy, 28-day all-cause mortality, etc) and adverse event (renal injury, nervous system, skin pigmentation, etc) were collected from the two groups.
RESULTS: A total of 90 patients were enrolled, including 22 patients in the CRRT group and 68 patients in the non-CRRT group. (1) There was no significant difference in gender, age, basic diseases, liver function, infection of pathogens and sites, colistin sulfate dose between the two groups. Compared with the non-CRRT group, the acute physiology and chronic health evaluation II (APACHE II) and sequential organ failure assessment (SOFA) were higher in the CRRT group [APACHE II: 21.77±8.26 vs. 18.01±6.34, P < 0.05; SOFA: 8.5 (7.8, 11.0) vs. 6.0 (4.0, 9.0), P < 0.01], serum creatinine level was higher [μmol/L: 162.0 (119.5, 210.5) vs. 72.0 (52.0, 117.0), P < 0.01]. (2) Plasma concentration: there was no significant difference in steady-state trough concentration between CRRT group and non-CRRT group (mg/L: 0.58±0.30 vs. 0.64±0.25, P = 0.328), nor was there significant difference in steady-state peak concentration (mg/L: 1.02±0.37 vs. 1.18±0.45, P = 0.133). (3) Clinical efficacy: there was no significant difference in clinical response rate between CRRT group and non-CRRT group [68.2% (15/22) vs. 80.9% (55/68), P = 0.213]. (4) Safety: acute kidney injury occurred in 2 patients (2.9%) in the non-CRRT group. No obvious neurological symptoms and skin pigmentation were found in the two groups.
CONCLUSIONS: CRRT had little effect on the elimination of colistin sulfate. Routine blood concentration monitoring (TDM) is warranted in patients received with CRRT.
参考来源
- Peng D, Zhang F, Li Z, et al. [Effect of continuous renal replacement therapy on plasma concentration, clinical efficacy and safety of colistin sulfate]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2023. PMID: 36880245. doi:10.3760/cma.j.cn121430-20220906-00819
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。